About This Tool
The Mepolizumab Dose Calculator provides dosing recommendations based on approved indications and patient age groups. Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody used to treat several eosinophil-driven diseases. This guide summarizes the information used by the calculator but is not a substitute for clinical judgment or the full prescribing information.
Outputs Explained
After entering the required patient information, the calculator will provide the following outputs:
- Calculated Dose: The recommended dose of mepolizumab in milligrams (mg).
- Route of Administration: The recommended method for giving the medication, which is subcutaneous (SC) injection for all listed indications.
- Dosing Frequency: The standard interval between doses, typically every 4 weeks.
- Administration Notes: Important instructions, such as when a dose requires multiple injections to achieve the total recommended amount.
How to Use the Calculator
Follow these simple steps to determine the appropriate mepolizumab dose:
- Select Indication: Choose the patient's condition from the dropdown list (e.g., Severe Eosinophilic Asthma, EGPA).
- Enter Patient Age: Input the patient's age in years. This is a critical factor as dosing differs between adults and children.
- Enter Patient Weight (if required): The weight field will only appear if it is necessary for the calculation, specifically for children aged 6 to 11 years with Severe Eosinophilic Asthma.
- Calculate Dose: Click the "Calculate Dose" button to see the result. The tool will display an error message if the patient's age is outside the approved range for the selected indication.
Dosing Overview
Mepolizumab dosing is indication-specific and may vary by age. All doses are administered subcutaneously every 4 weeks.
| Indication | Patient Population | Recommended Dose |
|---|---|---|
| Severe Eosinophilic Asthma (SEA) | Adults and adolescents aged 12 years and older | 100 mg |
| Severe Eosinophilic Asthma (SEA) | Children aged 6 to 11 years | 40 mg |
| Eosinophilic Granulomatosis with Polyangiitis (EGPA) | Adults aged 18 years and older | 300 mg (as three 100 mg injections) |
| Hypereosinophilic Syndrome (HES) | Adults and adolescents aged 12 years and older | 300 mg (as three 100 mg injections) |
| Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Adults aged 18 years and older | 100 mg |
Switching Biologics
Switching a patient to mepolizumab from another biologic (e.g., another IL-5 inhibitor or an IgE inhibitor) should be done under the guidance of a specialist. There is no standard washout period, and the decision on timing the first dose of mepolizumab should be based on the clinical scenario, disease activity, and the pharmacokinetic properties of the previous biologic.
Missed Dose Protocol
If a patient misses a dose of mepolizumab, they should be instructed to administer it as soon as possible. The subsequent dose should be administered according to the established 4-week schedule. If the next regular dose is already due, the patient should not double the dose. Always refer to the official prescribing information for detailed guidance.
Safety Alerts
Healthcare professionals should be aware of key safety information associated with mepolizumab:
- Hypersensitivity Reactions: Serious reactions, including anaphylaxis, can occur after mepolizumab administration. These can happen hours or days after the injection. Patients should be monitored appropriately.
- Herpes Zoster Infections: An increased incidence of herpes zoster has been observed in patients treated with mepolizumab. Consider varicella vaccination for patients with no history of vaccination prior to starting therapy.
- Parasitic (Helminth) Infections: Eosinophils may be involved in the immune response to some helminth infections. Treat patients with pre-existing infections before starting mepolizumab.
Frequently Asked Questions
Why is patient weight not required for adults?
For adults and adolescents (12+), mepolizumab is administered as a fixed dose regardless of weight. Weight-based dosing is not part of its approved labeling for these age groups across all indications. The calculator only requests weight for children with SEA aged 6-11, where it was studied.
How is the 300 mg dose for EGPA or HES administered?
The 300 mg dose is administered as three separate 100 mg subcutaneous injections at the same visit. The injections should be given at least 5 cm (approximately 2 inches) apart in recommended sites like the thigh, abdomen, or upper arm.
Is mepolizumab approved for children with CRSwNP?
No. According to the prescribing information, mepolizumab is only indicated for adults aged 18 years and older for the treatment of Chronic Rhinosinusitis with Nasal Polyps. The calculator will show an error for patients under 18 for this indication.
What is the standard dosing frequency?
The standard administration frequency for mepolizumab for all approved indications is once every 4 weeks.
What should I do if the calculator shows an error for a specific age?
An error message indicates that mepolizumab is not approved for the specific indication and age combination you have entered. For example, it is not indicated for children under 6 for SEA or under 12 for HES.
Can this calculator be used for other IL-5 inhibitors like benralizumab or reslizumab?
No. This tool is exclusively for mepolizumab (Nucala). Other IL-5 inhibitors have different dosing regimens, routes of administration, and approved indications. Using this calculator for other drugs will result in incorrect information.
Does the calculator adjust dosing for renal or hepatic impairment?
No dose adjustment is required for patients with renal or hepatic impairment. The calculator does not have inputs for these conditions as clinical studies did not indicate a need for dose modification.
What is the mechanism of action of mepolizumab?
Mepolizumab is a monoclonal antibody that targets interleukin-5 (IL-5). By binding to IL-5, it prevents the cytokine from activating eosinophils, which reduces the production and survival of these key inflammatory cells.
References
- NUCALA (mepolizumab) Prescribing Information. U.S. Food and Drug Administration (FDA).
- Nucala (mepolizumab) Summary of Product Characteristics (SmPC). European Medicines Agency (EMA).
- Nucala for Healthcare Professionals. GlaxoSmithKline.
- Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
